Physician profile
Timothy Alton
NPI 1730404286
$1,529,098.55
in general payments reported to CMS, 2019-2025
12 companies · $386K in 2025
The $386K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $72K · 2021: $121K · 2022: $216K · 2023: $288K · 2024: $370K · 2025: $386K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $858K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $80K · Food and Beverage: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $857,557.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,762.50 |
| Travel and Lodging | $80,422.81 |
| Food and Beverage | $18,956.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,083,384.14 | 2019-2025 | Actis, Pinnacle, Attune |
| Kci USA, INC. | $218,690.27 | 2019-2023 | Prevena, Prevena Restor Arthroform, V.A.C. Veraflo |
| Depuy Synthes Products, INC. | $119,154.59 | 2022-2025 | Reclaim, Velys, Attune |
| Solventum Corporation | $65,648.25 | 2024-2025 | Prevena, Prevena Restor Arthroform, V.A.C. Veraflo Cleanse Choice |
| Biocomposites INC | $17,828.08 | 2019-2024 | |
| Ethicon Endo-Surgery INC. | $12,600.00 | 2023-2024 | |
| Depuy Synthes Sales INC. | $7,274.48 | 2019-2025 | Attune, Velys, Actis |
| Innovation Technologies INC | $3,993.98 | 2022 | |
| Zimmer Biomet Holdings, INC. | $466.85 | 2021-2024 | Rosa, Persona |
| Smith+Nephew, INC. | $24.90 | 2024 | Stravix |
| Medacta USA, INC. | $19.52 | 2020 | |
| Fidia Pharma USA INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Alton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.